New Insights into Alzheimer’s Disease and the Role of TSPO Protein

In a significant scientific advancement, a research team led by Dr. Thomas Giolarty, Dean of the Robert Stempel College of Public Health and Social Work at Florida International University, has explored the role of the TSPO protein in Alzheimer’s disease. This study opens new avenues for understanding how the disease develops and the possibility of delaying its progression.

The Importance of TSPO Protein

The TSPO protein, or the 18 kDa translocator protein, is a reliable biomarker used in diagnosing neuroinflammation in various neurodegenerative and psychiatric disorders. Dr. Giolarty, who has been studying this protein for over three decades, explains that this study is the first of its kind to investigate how this protein increases early and where it is elevated in the brain.

The research team utilized advanced imaging software to track TSPO levels in genetically modified mouse models of familial Alzheimer’s disease. They confirmed their findings using human brain tissues donated by individuals from the largest group of early-onset familial Alzheimer’s patients in the world, residing in Antioquia, Colombia.

The Role of the “Paisa” Genetic Mutation

The families studied carry the “Paisa” mutation, discovered by the late Dr. Francisco Lopera. This mutation causes symptoms to appear between the ages of 30 and 40, with affected individuals typically dying in their fifties. The study found that TSPO levels were elevated in mice in the subiculum region, a crucial part of the hippocampus, at an early age equivalent to 18 to 20 years in humans.

The research team noted that microglial cells, the brain’s primary immune cells, contained the highest levels of TSPO, especially those around amyloid plaques. Interestingly, female mice exhibited higher TSPO levels, reflecting real-world statistics where two-thirds of Alzheimer’s patients are women.

Questions About TSPO’s Function

The study’s findings raise new questions about TSPO’s role: Does it contribute to damage, or does it protect the brain? Could inhibiting or enhancing its function impact the progression of the disease? The team is now working on genetically modified mouse models lacking TSPO to explore these questions more deeply.

Additionally, the study is expanding to include sporadic late-onset Alzheimer’s cases, which account for over 90% of all diagnoses.

Conclusion

Dr. Daniel Martinez Perez, the study’s first author and a Ph.D. candidate in Giolarty’s lab, emphasizes that increased understanding of these processes brings us closer to developing treatments that can truly help combat Alzheimer’s disease before it’s too late. If the information gathered from this study can help delay Alzheimer’s progression by even five years, it could significantly improve patients’ lives and reduce the disease’s prevalence.